Hello, and welcome to the PDS Biotechnology First Quarter 2021 Earnings Call and Webcast. [Operator Instructions]. As a reminder, this conference is being recorded. It's now my pleasure to turn the ...
9 partial responses (3 cervical cancer, 2 vulvar/vaginal cancer, 2 anal cancer, 2 oropharyngeal cancer) 90% of these of these responses are ongoing after a median 5 months of follow up (9/10) The NCI ...
FLORHAM PARK, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease ...
FLORHAM PARK, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease ...
Acquisition of PDS Life Sciences Consolidates Non-Clinical Market; Further Extends Instem’s Leadership in Study Management and Regulatory SEND Submission Support PHILADELPHIA--(BUSINESS WIRE)--Instem, ...
Good day, and thank you for standing by. Welcome to the Precision Drilling Corporation 2021 Third Quarter Results Conference Call. [Operator Instructions]. I would now like to hand the conference over ...
1 complete response (anal cancer) 9 partial responses (3 cervical cancer, 2 vulvar/vaginal cancer, 2 anal cancer, 2 oropharyngeal cancer) 90% of these of these responses are ongoing after a median 5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback